

VOLUME 291 (2016) PAGES 21984–22000

DOI 10.1074/jbc.A116.750653

Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.

Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Travis Nemkov, Brett M. Stevens, Biniam Adane, Nabilah Khan, Fred K. Hagen, Vinod K. Yadav, Subhajyoti De, John M. Ashton, Kirk C. Hansen, Jonathan A. Gutman, Daniel A. Pollyea, Peter A. Crooks, Clayton Smith, and Craig T. Jordan

The University of Arkansas for Medical Sciences and Dr. Peter A. Crooks have financial interests in melampomagnolide B (MMB) and structurally related analogs discussed in this manuscript. These financial interests have been reviewed and approved in accordance with the university's conflict of interest policies.

Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of these corrections as prominently as they carried the original abstracts.